Forecast

The analysts' average price target is €52.66 (+56.73%). The median is €53.74 (+59.94%).

Buy	13
Hold	1
Sell	0

News Go to news feed

Pharvaris shows phase‑III success: Deucrictibant reduces HAE attacks by 87%

At the Cantor Fitzgerald conference Pharvaris presented phase‑III data (CHAPTER‑3) showing an 87% reduction in hereditary angioedema attacks with the oral B2‑receptor antagonist Deucrictibant. The study included patients from six continents and used an extended‑release formulation that may explain the improved efficacy profile. Safety questions remain: two grade‑3 elevations in liver enzymes and one serious laryngeal event were reported, though the company considers the overall profile comparable to existing prophylactics. Pharvaris plans to launch the on‑demand treatment on April 8, 2025, and aims to file for approval for prophylaxis in the first half of 2025, supported by a targeted commercial platform for bradykinin‑mediated angioedemas. » More on de.investing.com
Pharvaris: oral HAE drug deucrictibant shows strong phase‑III data

Deucrictibant reduced HAE attacks by 87% in the phase‑III prophylaxis study in type‑1/ type‑2 patients (83% in the overall population) and replicated earlier results in a larger, global cohort. Pharvaris expects a PDUFA date for the on‑demand formulation on April 23 and plans to submit the regulatory application for the prophylaxis version in H1 2025. Two cases of elevated liver enzymes were reported but, according to management, are comparable to known risks; long‑term safety is being investigated in the open‑label extension study CHAPTER‑4. Commercially, the company intends to target treatment‑naive patients as well as users of ORLADEYO and injectable therapies. » More on de.investing.com
Pharvaris rises sharply after positive phase‑3 data for HAE drug

Pharvaris reported statistically significant topline results from the pivotal phase‑3 study CHAPTER‑3: Deucrictibant XR reduced the mean monthly HAE attack rate by 83% versus placebo (p<0.0001) and lowered the rate in HAE type 1/2 by 87%. All secondary endpoints were significant and the safety profile proved well tolerated. The company intends to use the data for regulatory submissions, including a New Drug Application in the US in the first half of 2027, and the stock then reached a new 52‑week high. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Pharvaris Aktie has already paid €0.10 in dividends. The last payout was in July 2022.

Financials

In the last quarter, Pharvaris Aktie had revenue of €0 and net profit of -€47.84m

(EUR)	June 2026	YoY
Revenue	0	-
Gross profit	0	-
Net profit	-47.84m	5.19%
EBITDA	-50.66m	12.15%

Fundamentals

Metric	Value
Market capitalization	€2.35bn
Number of shares	69.88m
52-week high/low	€37.49 - €17.90
Dividends	No
Beta	-2.32
P/E ratio	-12.47
PEG ratio	-0.97
P/B ratio	7.62
P/S ratio	0.00

Company profile

Pharvaris N.V., ein biopharmazeutisches Unternehmen in der klinischen Phase, konzentriert sich auf die Entwicklung und Vermarktung von Therapien für seltene Krankheiten. Das Unternehmen entwickelt PHA121, einen niedermolekularen Bradykinin-B2-Rezeptor-Antagonisten, der sich in einer klinischen Phase-II-Studie zur Behandlung des hereditären Angioödems (HAE) befindet. Darüber hinaus entwickelt das Unternehmen PHVS416, eine Weichkapsel, die bei Bedarf schnell freigesetzt wird, für Patienten, die unter akuten HAE-Attacken leiden, und befindet sich in einer klinischen Phase-2-Studie; und PHVS719, eine prophylaktische Tablette mit verlängerter Wirkstofffreisetzung für HAE-Patienten, die sich in einer klinischen Phase-1-Studie befindet. Das Unternehmen ist in den Niederlanden, der Schweiz und den Vereinigten Staaten tätig. Das Unternehmen wurde 2015 gegründet und hat seinen Sitz in Leiden in den Niederlanden.